Clinical trials: LAM
HIV-1 Infection
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine…
- Trial name
- NCT02603120
- Testing
- ABC/DTG/3TC, B/F/TAF
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 567 people
- Sponsor
- Gilead Sciences
Acquired Immunodeficiency Syndrome
Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
To investigate the efficacy and tolerability of the regimen of dolutegravir plus lamivudine in HIV infected adults who are virologically suppressed and with evidence of TDF toxicity.
- Trial name
- NCT05493969
- Testing
- Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
- Volunteers
- 100 people
- Sponsor
- Shanghai Public Health Clinical Center
Infection, Human Immunodeficiency Virus, HIV Infections
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (Tenofovir…
- Trial name
- NCT02831673
- Testing
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 719 people
- Sponsor
- ViiV Healthcare
Lymphangioleiomyomatosis, Tuberous Sclerosis
Doxycycline In Lymphangioleiomyomatosis (LAM)
The purpose of the study is to test if the drug doxycycline is effective in slowing the progression of lung disease in LAM. Lymphangioleiomyomatosis (LAM) is a rare lung disease which affects young women.
- Trial name
- NCT00989742
- Testing
- Doxycycline
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Nottingham
Lymphangioleiomyomas, Tuberous Sclerosis
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
This study will examine the effect of fasting on lymphangioleiomyomas abdominal tumors formed from enlarged lymph nodes containing lymphatic fluid.
- Conditions
- Lymphangioleiomyomas, Tuberous Sclerosis, Lymphangioleiomyomatosis
- Trial name
- NCT00552955
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
To evaluate the safety and tolerance of the combination of adefovir dipivoxil at two comparative doses and nelfinavir plus saquinavir SGC administered orally (Group 1) vs.
- Trial name
- NCT00002184
- Testing
- Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B
Antiviral resistance mutations limit the efficacy of therapy for chronic hepatitis B. At year 2, resistance to adefovir may occur as high as 25% in patients with history of lamivudine resistance.
- Trial name
- NCT00531167
- Testing
- combination of lamivudine+adefovir vs entecavir
- Where
- 2 sites in South Korea
- Volunteers
- 219 people
- Sponsor
- Korea University
Lymphangioleiomyomatosis
LAM Pilot Study With Imatinib Mesylate
This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).
- Trial name
- LAMP-1 (NCT03131999)
- Testing
- Imatinib Mesylate 400Mg Capsule
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Iron, Acute Myeloid Leukemia
Metabolism Des LAM
In this study, the investigators study the prognostic role of oxidative stress metabolism and iron in Acute myeloid leukemia.
- Conditions
- Iron, Acute Myeloid Leukemia, Diagnosis, Oxydative Stress
- Trial name
- LAM-ROS (NCT02176109)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Grenoble
HIV Infections
The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection
To evaluate the ability of the combination of indinavir, zidovudine, and lamivudine to suppress HIV-1 infection as measured by: (1) the maintenance of HIV-1 serum viral RNA below the limit of detection of the most sensitive…
- Trial name
- NCT00002179
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 17 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
Retinal Detachment, Rhegmatogenous Retinal Detachment
Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the eye and reduces blood markers of inflammation in people who undergo retinal detachment surgery (pars plana vitrectomy).
- Trial name
- NCT06056596
- Testing
- Lamivudine 300 MG
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
HIV Infections, AIDS-Associated Nephropathy
A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease
The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir plus d4T in patients with HIV-associated kidney…
- Trial name
- NCT00002397
- Testing
- Nelfinavir mesylate, Saquinavir, Lamivudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Body Weight Changes, Human Immunodeficiency Virus
Doravirine and Weight Gain in Antiretroviral Naive
The purpose of this study is determine whether different antiretroviral therapy (ART) changes the effects on body fat and predict the weight change in Black and Hispanic females.
- Conditions
- Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity
- Trial name
- DAWN (NCT05457530)
- Testing
- DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Prism Health North Texas
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
HIV Infections, HIV-1-infection
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of Lamivudine (150 mg BID) plus Raltegravir (400 mg BID) switching to Lamivudine (300 mg QD)…
- Conditions
- HIV Infections, HIV-1-infection, HIV Seropositivity
- Trial name
- NCT03311945
- Testing
- Raltegravir, Lamivudine
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Judit Pich
HIV Infection
Triple vs. Double Therapy in naïves HIV-Infected Patients
The objective of this study is to clarify whether if starting antiretroviral treatment based on dual therapy (DTG + 3TC) could provide less control of residual HIV replication and, therefore, a detriment on immune activation and…
- Trial name
- TRIDUNA (NCT04295460)
- Testing
- Randomize
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
HIV Infections
When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
The purpose of this study is to determine when HIV infected children should begin taking anti-HIV medications in order to improve both patient quality of life and survival.
- Trial name
- NCT00234091
- Testing
- Abacavir, Efavirenz, Lamivudine
- Where
- 9 sites in Cambodia, Thailand
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
- Trial name
- NCT00002190
- Testing
- Saquinavir, Lamivudine, Zidovudine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Lymphangioleiomyomatosis, Pulmonary Hypertension
Pulmonary Hypertension in Lymphangioleiomyomatosis
This is a descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension.
- Trial name
- LAM-PH (NCT00960895)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
This single arm study will evaluate the efficacy and safety of PEGASYS in patients with lamivudine resistant HBeAg negative chronic hepatitis B. Patients will receive PEGASYS 180 micrograms s.c.
- Trial name
- NCT00460850
- Testing
- peginterferon alfa-2a (40KD) [PEGASYS]
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche